Aspirin use associated with a reduced risk of HCC in hepatitis B patients

Share this content:
The researchers found that the cumulative incidence of hepatocellular carcinoma in the aspirin group was significantly lower than that in the untreated group in 5 years.
The researchers found that the cumulative incidence of hepatocellular carcinoma in the aspirin group was significantly lower than that in the untreated group in 5 years.

(HealthDay News) — Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma (HCC), according to a study scheduled for presentation at The Liver Meeting, held by the American Association for the Study of Liver Diseases from Oct. 20 to 24 in Washington, DC.

Teng-Yu Lee, MD, PhD, from Taichung Veterans General Hospital in Taiwan, and colleagues used data from Taiwan's National Health Insurance Research Database from 1998 to 2012. Patients with non-hepatitis B infections were excluded, as were those with HCC before the follow-up index dates. A total of 1,553 patients who continuously received daily aspirin ≥90 days were randomly matched (1-to-4 ratio) with 6,212 patients who never received anti-platelet therapy based on baseline characteristics, the index date, and nucelos(t)ide analogue (NA) use during follow-up.

The researchers found that the cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in 5 years (2.86% vs 5.59%). Aspirin therapy was independently associated with a reduced HCC risk (hazard ratio [HR], 0.63) in a multivariable regression analysis. An increased HCC risk was independently associated with older age (HR, 1.03 per year), male gender (HR, 2.65), cirrhosis (HR, 1.89), and diabetes mellitus (HR, 1.51). NA (HR, 0.57) and statin (HR, 0.57) use were associated with a decreased HCC risk.

"For effectively preventing HBV‐related liver cancer, the findings of this study may help hepatologists treat patients with chronic HBV infection in the future, particularly for those who are not indicated for antiviral therapy. We are pursuing prospective investigations for further confirming the findings," Lee said in a statement.

One author disclosed financial ties to the pharmaceutical industry.

Reference

Lee TY, Hsu YC, Yu SH, et al. Association of aspirin therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology. 1 Oct 2017. DOI: 10.1002/hep.29500

You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Hepatology Information Center

Sign Up for Free e-newsletters